Words by GOLD newsdesk
Sanofi is set to cut the pricing of its insulin products from 99 USD a month to 35 USD a month, in a massive step toward greater access to medicine within the US.
This new initiative from Sanofi updates its ‘Insulins Valyou Savings Program’ and follows similar drops in price from Novo Nordisk and Eli Lilly in recent years. The country may soon be establishing a ceiling of 35 USD a month for insulin across the board for Medicare Part D beneficiaries, with a measure passed by the House of Representatives regarding this currently awaiting review by the senate.
Adam Gluck, Head of US and Global Specialty Care Corporate Affairs at Sanofi commented that “informed by patient feedback, Sanofi has updated our industry-leading assistance program to continue addressing access and affordability challenges for all people living with diabetes, regardless of insurance coverage”.
According to the Centers for Disease Control and Prevention (CDC), 37.3m people in the US have diabetes, making up 11.3% of the US population. Diabetes is on the rise within the US and the decision to cut prices comes at a time of great public scrutiny toward the cost of insulin in the region.
